Analysts forecast that Crocs, Inc. (NASDAQ:CROX) will report $201.67 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Crocs’ earnings. The highest sales estimate is $204.90 million and the lowest is $200.00 million. Crocs reported sales of $199.11 million during the same quarter last year, which indicates a positive year over year growth rate of 1.3%. The company is expected to issue its next quarterly earnings results on Wednesday, February 27th.
According to Zacks, analysts expect that Crocs will report full-year sales of $1.07 billion for the current fiscal year, with estimates ranging from $1.07 billion to $1.08 billion. For the next year, analysts expect that the business will report sales of $1.13 billion, with estimates ranging from $1.12 billion to $1.13 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Crocs.
Crocs (NASDAQ:CROX) last issued its quarterly earnings results on Thursday, November 8th. The textile maker reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.09. Crocs had a return on equity of 17.27% and a net margin of 3.08%. The company had revenue of $261.10 million for the quarter, compared to analyst estimates of $246.47 million. During the same quarter last year, the company posted ($0.03) EPS. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year.
CROX has been the topic of a number of analyst reports. BidaskClub upgraded Crocs from a “hold” rating to a “buy” rating in a research report on Saturday, September 15th. Zacks Investment Research downgraded Crocs from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 10th. Piper Jaffray Companies set a $23.00 price target on Crocs and gave the stock a “buy” rating in a research note on Monday, October 22nd. Pivotal Research set a $25.00 price objective on Crocs and gave the stock a “buy” rating in a research note on Tuesday, November 6th. Finally, UBS Group raised Crocs to a “neutral” rating in a research note on Monday, November 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $17.14.
Institutional investors have recently bought and sold shares of the business. NumerixS Investment Technologies Inc purchased a new position in shares of Crocs during the second quarter valued at approximately $137,000. Harvest Fund Management Co. Ltd bought a new stake in Crocs in the 3rd quarter worth approximately $171,000. Pacer Advisors Inc. grew its position in Crocs by 133.5% in the 3rd quarter. Pacer Advisors Inc. now owns 9,556 shares of the textile maker’s stock worth $203,000 after purchasing an additional 5,463 shares during the period. Aperio Group LLC bought a new stake in Crocs in the 2nd quarter worth approximately $179,000. Finally, Verition Fund Management LLC bought a new stake in Crocs in the 3rd quarter worth approximately $229,000.
Shares of CROX stock opened at $27.09 on Friday. The firm has a market cap of $1.78 billion, a P/E ratio of -1,354.50, a PEG ratio of 5.12 and a beta of 0.61. Crocs has a twelve month low of $10.53 and a twelve month high of $28.20.
Crocs, Inc, together with its subsidiaries, designs, develops, manufactures, markets, and distributes casual lifestyle footwear and accessories for men, women, and children worldwide. It offers various footwear products, including clogs, sandals, flips and slides, shoes, and boots under the Crocs brand name.
Further Reading: What is cost of equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crocs and related companies with MarketBeat.com's FREE daily email newsletter.